Drugs and Valvular Heart Disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In 1997, Connolly et al. reported that both racemic fenfluramine (Pondimin) and dexfenfluramine (Redux) were associated with valvular heart disease.1 The valvular abnormalities seen in patients treated with these agents were distinctive. On echocardiography, leaflet thickening as well as chordal thickening and retraction were observed. Surgically removed valves were noted to have a glistening white surface, with histologic evidence of a plaque-like process extending along the leaflet surfaces and encasing the chordae tendineae. These findings were similar to those in patients with heart-valve damage induced by serotonin-secreting carcinoid tumors.1 This association of racemic fenfluramine and dexfenfluramine with valvular heart disease . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, valvular heart disease is associated with anorectic agents, such as fenfluramine, and antimigraine medications, such as ergot-amine, via serotonin 5-HT2B receptor agonism66.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [66]
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1223 · Cited by 304
Self-citationAppetite Suppressants and Valvular Heart Disease
Devereux, R. B. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391109 · Cited by 53
Setola, V., & Roth, B. L. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.377 · Cited by 48
Self-citation
Cited by
Items 401–500 of 503
ENFERMEDAD DE PARKINSON, PROYECCIONES FUTURAS, DIAGNÓSTICO PRECOZ, TRATAMIENTO TEMPRANO
Gershanik, O. S. (2008) · Revista Médica Clínica Las Condes · Cited by 1
Cardiovascular oxidative stress: recent findin gs on ACE2 And MAO
Alfonso, R. M., & Silva, P. (2012) · Cited by 1
Chapter 21 Valvular Heart Disease
Vahanian, A. S., Iung, B., Piérard, L., Dion, R. A. E., & Pepper, J. (2009) · Cited by 1
Quinagolide compared with cabergoline in the prevention of ovarian hyperstimulation syndrome
Kamel, R., Hanafy, A., Omran, E., Halwagy, A. E. S. E., & Shaheen, A. (2016) · Evidence Based Women s Health Journal · doi:10.1097/01.ebx.0000440884.67667.d1 · Cited by 1
Fouad, M., Latif, H. A. A. E., Yamani, M. E., Galal, M. A., Kamal, S., & Sindi, I. A. (2021) · Current Therapeutic Research · doi:10.1016/j.curtheres.2021.100647 · Cited by 1
Perspective Chapter: The Role of Dopamine Receptors in Neuropsychiatric Diseases
Yaman, B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001592 · Cited by 2
A current view on dopamine receptor agonists in the treatment of Parkinson’s disease
Titova, N. (2015) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20151159176-83 · Cited by 1
Peker, E. G. G., Balabanlı, B., ÖZER, Ç., & Cevher, Ş. C. (2021) · Journal of Anatolian Environmental and Animal Sciences · doi:10.35229/jaes.929547 · Cited by 2
Maciejewski, M., Lounkine, E., Hartmann, A., Whitebread, S., & Urbán, L. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch03 · Cited by 1
Current Social, Clinical, and Scientific Environment of Pharmaceutical R&D
Urbán, L., Valentin, J., Kaitin, K. I., & Wang, J. (2014) · Wiley eBooks · doi:10.1002/9781118783344.ch1 · Cited by 1
De Novo Design of Ligands against Multitarget Profiles
Besnard, J., & Hopkins, A. L. (2013) · Wiley eBooks · doi:10.1002/9783527677016.ch12 · Cited by 2
Pituitary-directed medical treatment of Cushing’s disease
Arnaldi, G., Cardinaletti, M., Trementino, L., Tirabassi, G., & Boscaro, M. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.10 · Cited by 2
Serotonin receptors offer clues to new antidepressants
Frood, A. (2013) · Nature · doi:10.1038/nature.2013.12659 · Cited by 1
Levy, R. J., Fitzpatrick, E., Castillero, E., Shukla, H. J., Inamdar, V. V., Aghali, A., Grau, J. B., Rioux, N., Salvati, E., Keeney, S. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.10.985382 · Cited by 2
Non‐Surgical Management of Obesity
Hanson, P., & Barber, T. M. (2022) · Wiley eBooks · doi:10.1002/9781119521686.ch5 · Cited by 1
5-Hydroxytryptamine Receptor 2B
Doly, S., Diaz, S. L., Belmer, A., Roumier, A., & Maroteaux, L. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0461-4_286 · Cited by 1
Infertility and reproductive endocrinology
Bieber, E. J., Sanfilippo, J. S., Horowitz, I., & Shafi, M. I. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139628938.058 · Cited by 1
Integrated Risk Assessment of Cardiovascular Safety in Drug Discovery
Erdemli, G., & Martin, R. L. (2014) · Wiley eBooks · doi:10.1002/9781118783344.ch18
Xu, J. J., Ekins, S., McGlashen, M. L., & Lauffenburger, D. A. (2008) · Wiley eBooks · doi:10.1002/9780470431818.ch14
Pathological Conditions Associated with the Disturbance of the 5‐HT System
Hoyer, D. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch04 · Cited by 1
Neuropharmacological studies of Parkinson´s disease with some emphasis on serotonin transmission
Zhang, X. (2008) · Figshare
Geneesmiddelen en hartklepafwijkingen
van der Does, E. (2007) · Medisch-Farmaceutische Mededelingen · doi:10.1007/bf03059017
Phentermine cardiovascular safety II: Response to Yosefy Int J Cardiol. 2009 Epub Mar 19
Rothman, R. B., & Hendricks, E. J. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.02.060
Phentermine cardiovascular safety
Rothman, R. B., & Hendricks, E. J. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.12.205
Insuffisance aortique sous faibles doses de cabergoline pour hyperprolactinémie non tumorale
Belleville, I., Chague, F., Petit, J., & Boujon, B. (2007) · Annales d Endocrinologie · doi:10.1016/j.ando.2007.08.003
Conceptualizing Drug Therapies as Risk Factors for Chronic Disease
Berall, L. E., Choptiany, J. R., Gill, S. S., Bell, C. M., Rochon, P. A., & Gruneir, A. (2011) · Aging Health · doi:10.2217/ahe.10.93
Cannabinoid Regulation of Serotonin 2A (5-HT 2A ) Receptor Signaling
Franklin, J. M. (2013)
Rapidly Progressing Mitral Regurgitation After Cabergolin Treatment
Uz, Ö., Kardeşoğlu, E., Aparcı, M., Özmen, N., & Cebeci, B. S. (2008) · DergiPark (Istanbul University)
Dopamine Agonists and the Risk for Valvular Heart Disease
Krumholz, H. M., & Sm (2007) · Journal watch · doi:10.1056/jc200701030000002
Christianson, M. S., King, J. A., & Zacur, H. A. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139628938.062
Engineering GPCR signaling pathways with
Hsiao, E. C., Claeysen, S., Dumuis, A., Srinivasan, S., Forsayeth, J., Guettier, J., Chang, W.-C., Pei, Y., McCarthy, K. D., Nissenson, R. A., et al. (2008)
Self-citationMonoaminergic Approaches for Treatment of Schizophrenia
Rotella, D. P. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00035
Dopamine Agonists and Heart Valve Changes
Sudarsky, L. R. (2007) · Journal watch · doi:10.1056/jn200701300000002
Roth, B. L. (2007) · Assay and Drug Development Technologies · doi:10.1089/adt.2007.9987
“5 In terms of basic science, the ultimate validation you can get for molecular target data is clinical trial data supporting the findings.”
Self-citation10.2 Neuropharmacological Profiles of Antipsychotic Drugs
Roth, B. L., & Rogan, S. C. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195373035.003.0037
Self-citationJollis, J. G. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2262-8.00078-5
Anticoagulation treatment in patients with a mechanical heart valve
Grzymala-Lubanski, B. (2016) · DiVA at Umeå University (Umeå University)
Central nervous system stimulants and drugs that suppress appetite
Sequeira, R. P. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00001-5
Nieto, C., Rayo, I., Casas-Engel, M. D. L., Izquierdo, E., Alonso, B., Vega, M. A., & Corbí, A. L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/587709
Capulli, A. K. (2017) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Ferrari, G. M., & Grau, J. B. (2019) · Springer eBooks · doi:10.1007/978-3-7091-4874-7_41
Prolactin-Secreting Pituitary Adenomas: Clinical Management
Faje, A. T., Zachariah, M. A., & Swearingen, B. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-11836-5_8
In silico strategies to study polypharmacology of G-protein-coupled receptors
Hajjo, R. (2010) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/xtc7-2969
Alcántara‐Vázquez, O., Villamil‐Hernández, M. T., Sánchez‐López, A., Pertz, H. H., Villalón, C. M., & Centurión, D. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0591
“In fact, heart valve tissue fibrosis, pulmonary arterial fibrosis and hypertension involve activation of 5-HT2A receptors and/or 5-HT2B receptors (Connolly et al. 2009; Fabre et al. 2008; Kekewska et al. 2012; Launay et al. 2002; Roth 2007).”
BackgroundMedical treatment of Parkinson disease
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00006-8 · Cited by 2
Enhanced Affinity for 3-Amino-Chromane-Derived σ1 Receptor Ligands
Porter, M. R., Xiao, H., Maity, S., Vail, N. R., Smith, S. B., & Topczewski, J. J. (2020) · ACS Omega · doi:10.1021/acsomega.0c05117
Docking of highly selective peptide ligands of 5HT2A/C receptors with antipsychotic activity
Orlova, A. B., Sventitskaya, A. M., Vengerovich, N. G., Никифоров, А. С., Ivanov, I. M., & Proshina, Y. A. (2021) · Pharmacy Formulas · doi:10.17816/phf61345
Endocrine Disorders that Cause Diabetes
Hanley, N. A. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch17 · Cited by 3
Genetics and Epigenetics of Suicidal Behavior
Bani‐Fatemi, A. (2018) · TSpace (University of Toronto)
Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists
Gabalec, F., Cap, J., & Radocha, J. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.113
Yerly, P., & Vachiéry, J.-L. (2011)
Davis, J. R., & Święcicka, A. (2022) · doi:10.1093/med/9780198870197.003.0156
(2008) · CRC Press eBooks · doi:10.1201/9780849378812.ch4
Maroteaux, L., Roumier, A., Doly, S., Diaz, S. L., & Belmer, A. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_286-1
Hyperprolactinaemic anovulation
Davis, J. R. (2011) · doi:10.1093/med/9780199235292.003.0846
Parkinson’s Disease - Animal Models, Current Therapies and Clinical Trials
Yenisetti, S. C., Koza, Z., Kumar, D., Singh, S. K., & Ganeshpurkar, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100831
Medical therapy of pituitary adenomas
Molitch, M. E. (2024) · Brain medicine : · doi:10.61373/bm024i.0127
Dopamine receptor drugs and their applications
Lane, J. R., & Bonifazi, A. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-29867-7.00013-x
Psychedelic agents for treatment-resistant depression
Gukasyan, N., & Griffiths, R. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00014-1
The polypharmacological profiles of xanomeline and N‐desmethylxanomeline
Sakamoto, K., Huang, X., Albert, T. L., Knobloch, P. M., Foland, G. K., & Roth, B. L. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70460
“…et al., 2015), anorectic agents such as fenfluramine (Rothman et al., 2000), some anti-Parkinsonian medications and anti-migraine medications (Roth, 2007), 3,4-methylenedioxymethamphetamine (also known as MDMA) (Setola et al., 2003) and many other approved medications and drugs of abuse…”
Self-citationSynthesis and Evaluation of Novel Aza-Aromatics as Dual 5-HT2A and 5-HT2C Receptor Agonists
Adhikari, A. S., Yadav, A. K., Pandit, S., Kumar, S. G., Pandey, V. K., Maurya, A. K., Umrao, D., Chand, D., Maity, D., Gayen, J. R., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00505
Implication de la sérotonine et des récepteurs 5-HT2 dans le remodelage valvulaire cardiaque
Lawson, R. (2014) · theses.fr (ABES) · doi:10.70675/dc62fcffzf02fz40a2z9b20zc00f88a9d745 · Cited by 1
Mestre, J. L. (2018) · theses.fr (ABES) · doi:10.70675/cab4c4e4z049az4c9czbbefzbf46cdba1d44 · Cited by 1
Almandil, N. B., AbdulAzeez, S., Gomaa, M., Ibrahim, A., John, S., Prathas, S., Dhas, T. S., & Borgio, J. F. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s587705
“42,43 However, medications that promiscuously work against the related receptor could lead to life-threatening adverse effects.”
Yang, G., Zhong, Y., Jiao, H., Tao, Y., & Guo, Q. (2026) · The FASEB Journal · doi:10.1096/fj.202504731rr
“These include the anti-migraine drugs methysergide and ergotamine [22], the anti-parkinsonian medications pergolide and cabergoline [23], and drugs used to treat pituitary adenomas.”
Hammad, A., Ananthaneni, S., Khraisat, O., Ahmad, A., Munshi, H., Al-Ashqar, R., Patel, R., Goparaju, P., Dajani, A. R., Shamoon, F. E., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001387
Baldini, S., Schifano, N., Fernando, K., Coschignano, M., Villano, A., Zais, I. E., Antonini, G., Capogrosso, P., & Dehò, F. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00894-y
Mechanistic Basis for 5-HT2AR Over 5-HT2BR Activation
Tang, L., Ji, X., Wang, Y., Cao, D., Li, H., He, L., Cheng, J., & Wang, S. (2026) · Nature Communications · doi:10.1038/s41467-026-77659-x
Structure-based design of subtype-selective psychedelic analogs
Li, H., Tang, L., Zhang, J., Meng, B., Cao, D., Chen, Y., Yu, J., Wang, H., Liu, Z., Wang, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77658-y
BindingDB Entry 50046175: GPCR crystal structures: Medicinal chemistry in the pocket.
BindingDB (2016) · UC San Diego · doi:10.7270/q2mc91s4
BindingDB (2011) · UC San Diego · doi:10.7270/q2s182rt
BindingDB (2012) · UC San Diego · doi:10.7270/q2tb15g7
BindingDB (2010) · UC San Diego · doi:10.7270/q2b56jt3
BindingDB Entry 50015428: Activity of
BindingDB (2023) · UC San Diego · doi:10.7270/q2js9vbr
BindingDB (2021) · UC San Diego · doi:10.7270/q2h998p2
BindingDB Entry 50020245: 2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.
BindingDB (2024) · UC San Diego · doi:10.7270/q26h4nwp
BindingDB (2021) · UC San Diego · doi:10.7270/q2ks6w2r
BindingDB (2021) · UC San Diego · doi:10.7270/q28d00qn
BindingDB Entry 50011704: Design and Discovery of Functionally Selective Serotonin 2C (5-HT
BindingDB (2022) · UC San Diego · doi:10.7270/q28p6455
Metadata
- Authors
- Roth, B. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Roth, Bryan L.
- ORCID
- Roth, Bryan L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-01-04
- Volume
- 356
- Issue
- 1
- Pages
- 6-9
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1965258805
- Cited by
- 479
- References
- 7
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 11 · 2023: 14 · 2022: 20 · 2021: 18 · 2020: 17 · 2019: 18 · 2018: 20 · 2017: 19 · 2016: 30 · 2015: 29 · 2014: 25 · 2013: 32 · 2012: 28
- FWCI
- 35.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- fenfluramine, dexfenfluramine, valvular heart disease, drug-induced valvular disease, leaflet thickening, echocardiographic findings
- MeSH terms
- Cabergoline, Antiparkinson Agents, Ergolines, Heart Valve Diseases, Humans, Pergolide, Serotonin Receptor Agonists, Dopamine Agonists, Receptor, Serotonin, 5-HT2B, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.